Sun Pharma Units Settle US Case for $200 Million

Sun Pharmaceutical Industries Ltd. said Thursday its subsidiaries—Sun Pharmaceutical Industries Inc. and Taro Pharmaceuticals USA Inc.—have settled an antitrust litigation related to generic drug pricing in Pennsylvania, US.

As part of the agreement, the two entities will pay $200 million (₹17.0 billion) to the “End Purchaser Plaintiffs” to resolve all claims. The final payout may be lower if a portion of insured class members opt out, the company said in a filing.
The settlement represents nearly 16% of Sun Pharma’s consolidated net profit in 2024–25.